These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 31705526)
1. Guselkumab is superior to fumaric acid esters in patients with moderate-to-severe plaque psoriasis who are naive to systemic treatment: results from a randomized, active-comparator-controlled phase IIIb trial (POLARIS). Thaçi D; Pinter A; Sebastian M; Termeer C; Sticherling M; Gerdes S; Wegner S; Krampe S; Bartz H; Rausch C; Mensch A; Eyerich K Br J Dermatol; 2020 Aug; 183(2):265-275. PubMed ID: 31705526 [TBL] [Abstract][Full Text] [Related]
2. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 12-week efficacy, safety and speed of response from a randomized, double-blinded trial. Blauvelt A; Papp K; Gottlieb A; Jarell A; Reich K; Maari C; Gordon KB; Ferris LK; Langley RG; Tada Y; Lima RG; Elmaraghy H; Gallo G; Renda L; Park SY; Burge R; Bagel J; Br J Dermatol; 2020 Jun; 182(6):1348-1358. PubMed ID: 31887225 [TBL] [Abstract][Full Text] [Related]
3. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. Sbidian E; Chaimani A; Garcia-Doval I; Do G; Hua C; Mazaud C; Droitcourt C; Hughes C; Ingram JR; Naldi L; Chosidow O; Le Cleach L Cochrane Database Syst Rev; 2017 Dec; 12(12):CD011535. PubMed ID: 29271481 [TBL] [Abstract][Full Text] [Related]
4. A phase 4, randomized, head-to-head trial comparing the efficacy of subcutaneous injections of brodalumab to oral administrations of fumaric acid esters in adults with moderate-to-severe plaque psoriasis (CHANGE). Pinter A; Hoffmann M; Reich K; Augustin M; Kaplan K; Gudjónsdóttir SD; Delvin T; Mrowietz U; J Eur Acad Dermatol Venereol; 2021 Mar; 35(3):701-711. PubMed ID: 32939860 [TBL] [Abstract][Full Text] [Related]
5. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial. Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114 [TBL] [Abstract][Full Text] [Related]
6. Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial. Sticherling M; Mrowietz U; Augustin M; Thaçi D; Melzer N; Hentschke C; Kneidl J; Sieder C; Reich K Br J Dermatol; 2017 Oct; 177(4):1024-1032. PubMed ID: 28580646 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of fumaric acid esters in young patients aged 10-17 years with moderate-to-severe plaque psoriasis: a randomized, double-blinded, placebo-controlled trial. Hamm H; Wilsmann-Theis D; Tsianakas A; Gambichler T; Taipale K; Lauterbach J; Freudensprung U; Makepeace C; Br J Dermatol; 2021 Jul; 185(1):62-73. PubMed ID: 33332574 [TBL] [Abstract][Full Text] [Related]
8. A head-to-head comparison of ixekizumab vs. guselkumab in patients with moderate-to-severe plaque psoriasis: 24-week efficacy and safety results from a randomized, double-blinded trial. Blauvelt A; Leonardi C; Elewski B; Crowley JJ; Guenther LC; Gooderham M; Langley RG; Vender R; Pinter A; Griffiths CEM; Tada Y; Elmaraghy H; Lima RG; Gallo G; Renda L; Burge R; Park SY; Zhu B; Papp K; Br J Dermatol; 2021 Jun; 184(6):1047-1058. PubMed ID: 32880909 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: Results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. Blauvelt A; Papp KA; Griffiths CE; Randazzo B; Wasfi Y; Shen YK; Li S; Kimball AB J Am Acad Dermatol; 2017 Mar; 76(3):405-417. PubMed ID: 28057360 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to severe psoriasis with randomized withdrawal and retreatment: Results from the phase III, double-blind, placebo- and active comparator-controlled VOYAGE 2 trial. Reich K; Armstrong AW; Foley P; Song M; Wasfi Y; Randazzo B; Li S; Shen YK; Gordon KB J Am Acad Dermatol; 2017 Mar; 76(3):418-431. PubMed ID: 28057361 [TBL] [Abstract][Full Text] [Related]
11. Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial. Thaçi D; Eyerich K; Pinter A; Sebastian M; Unnebrink K; Rubant S; Williams DA; Weisenseel P Br J Dermatol; 2022 Jan; 186(1):30-39. PubMed ID: 33991341 [TBL] [Abstract][Full Text] [Related]
12. Fumaric acid esters in combination with a 6-week course of narrowband ultraviolet B provides an accelerated response compared with fumaric acid esters monotherapy in patients with moderate-to-severe plaque psoriasis: a randomized prospective clinical study. Tzaneva S; Geroldinger A; Trattner H; Tanew A Br J Dermatol; 2018 Mar; 178(3):682-688. PubMed ID: 29114862 [TBL] [Abstract][Full Text] [Related]
13. A 24-week multicentre, randomized, open-label, parallel-group study comparing the efficacy and safety of ixekizumab vs. fumaric acid esters and methotrexate in patients with moderate-to-severe plaque psoriasis naive to systemic treatment. Reich K; Augustin M; Thaçi D; Pinter A; Leutz A; Henneges C; Schneider E; Schacht A; Dossenbach M; Mrowietz U Br J Dermatol; 2020 Apr; 182(4):869-879. PubMed ID: 31376153 [TBL] [Abstract][Full Text] [Related]
14. A Phase 2 Trial of Guselkumab versus Adalimumab for Plaque Psoriasis. Gordon KB; Duffin KC; Bissonnette R; Prinz JC; Wasfi Y; Li S; Shen YK; Szapary P; Randazzo B; Reich K N Engl J Med; 2015 Jul; 373(2):136-44. PubMed ID: 26154787 [TBL] [Abstract][Full Text] [Related]
15. Guselkumab, an anti-interleukin-23 monoclonal antibody, for the treatment of moderate to severe plaque-type psoriasis in Japanese patients: Efficacy and safety results from a phase 3, randomized, double-blind, placebo-controlled study. Ohtsuki M; Kubo H; Morishima H; Goto R; Zheng R; Nakagawa H J Dermatol; 2018 Sep; 45(9):1053-1062. PubMed ID: 29905383 [TBL] [Abstract][Full Text] [Related]
16. Improvement in Patient-Reported Outcomes (Dermatology Life Quality Index and the Psoriasis Symptoms and Signs Diary) with Guselkumab in Moderate-to-Severe Plaque Psoriasis: Results from the Phase III VOYAGE 1 and VOYAGE 2 Studies. Armstrong AW; Reich K; Foley P; Han C; Song M; Shen YK; You Y; Papp KA Am J Clin Dermatol; 2019 Feb; 20(1):155-164. PubMed ID: 30417277 [TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of guselkumab in patients with psoriasis who have an inadequate response to ustekinumab: results of the randomized, double-blind, phase III NAVIGATE trial. Langley RG; Tsai TF; Flavin S; Song M; Randazzo B; Wasfi Y; Jiang J; Li S; Puig L Br J Dermatol; 2018 Jan; 178(1):114-123. PubMed ID: 28635018 [TBL] [Abstract][Full Text] [Related]
18. Safety and efficacy of guselkumab in Japanese patients with moderate-to-severe plaque psoriasis: a randomized, placebo-controlled, ascending-dose study. Nemoto O; Hirose K; Shibata S; Li K; Kubo H Br J Dermatol; 2018 Mar; 178(3):689-696. PubMed ID: 29222947 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial. Warren RB; Blauvelt A; Poulin Y; Beeck S; Kelly M; Wu T; Geng Z; Paul C Br J Dermatol; 2021 Jan; 184(1):50-59. PubMed ID: 32594522 [TBL] [Abstract][Full Text] [Related]
20. IL-23 blockade with guselkumab potentially modifies psoriasis pathogenesis: rationale and study protocol of a phase 3b, randomised, double-blind, multicentre study in participants with moderate-to-severe plaque-type psoriasis (GUIDE). Eyerich K; Weisenseel P; Pinter A; Schäkel K; Asadullah K; Wegner S; Muñoz-Elias EJ; Bartz H; Taut FJH; Reich K BMJ Open; 2021 Sep; 11(9):e049822. PubMed ID: 34518264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]